Valiant Labs Q4 FY26 Standalone Profit ₹353 Cr, Consolidated Profit ₹176 Cr
Valiant Laboratories reported audited standalone results for Q4 FY26 with revenue of ₹6,530 lakh and profit of ₹353 lakh. Consolidated revenue was ₹9,198 lakh with profit of ₹176 lakh. Full-year standalone revenue reached ₹21,704 lakh, and consolidated revenue was ₹23,747 lakh.
The announcement of financial results is a material event for investors and stakeholders. The standalone performance shows a significant profit, which is a positive indicator, though the consolidated full-year results are negative.
The company reported positive standalone net profit for the quarter and year, indicating improved performance on a standalone basis. While consolidated results show a loss for the full year, the quarterly consolidated profit is positive.
Valiant Laboratories Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved these results, along with the audit report issued by Raman S. Shah & Co., Chartered Accountants.
The standalone results for the quarter ended March 31, 2026, show a revenue from operations of ₹6,530.34 lakh and a net profit of ₹353.28 lakh. For the full year ended March 31, 2026, standalone revenue from operations stood at ₹21,704.25 lakh, with a net profit of ₹554.82 lakh.
On a consolidated basis, the revenue from operations for the quarter ended March 31, 2026, was ₹9,198.18 lakh, resulting in a net profit of ₹175.87 lakh. For the full year ended March 31, 2026, consolidated revenue from operations was ₹23,746.75 lakh, and the net profit was ₹(326.79) lakh.
The Board meeting commenced at 3:30 PM and concluded at 5:30 PM on May 14, 2026. The results are also available on the company's website.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.